CorMedix

CRMD

Market cap $562M

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March.

CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock.

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern.

CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.